Rifabutin

Edina Avdic, Pharm.D.
Pediatric Dosing Author: Lisa Hutchins, Pharm.D.
Rifabutin is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please log in or purchase a subscription.

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

Johns Hopkins Guides

MonkeypoxMonkeypox

Coronavirus COVID-19 (SARS-CoV-2)Coronavirus COVID-19 (SARS-CoV-2)

Suicide Risk in the COVID-19 PandemicSuicide Risk in the COVID-19 Pandemic

Moderna COVID-19 VaccineModerna COVID-19 Vaccine

BNT162b2 COVID-19 Vaccine (BioNTech/Pfizer)BNT162b2 COVID-19 Vaccine (BioNTech/Pfizer)

Managing Stress and Coping with COVID-19Managing Stress and Coping with COVID-19

Johnson & Johnson COVID-19 VaccineJohnson & Johnson COVID-19 Vaccine

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Prophylaxis of Mycobacterium avium complex (MAC) in patients with AIDS.
  • Treatment of H. pylori infections in combination with other agents.

NON-FDA APPROVED USES

  • Treatment of disseminated MAC in patients with AIDS (in combination with a macrolide plus ethambutol).
  • Treatment of TB in patients with AIDS who are taking PIs or NNRTIs.
  • Treatment of latent TB in patients intolerant to INH. Rifabutin x 4 months can be considered.

-- To view the remaining sections of this topic, please log in or purchase a subscription --

INDICATIONS

FDA

  • Prophylaxis of Mycobacterium avium complex (MAC) in patients with AIDS.
  • Treatment of H. pylori infections in combination with other agents.

NON-FDA APPROVED USES

  • Treatment of disseminated MAC in patients with AIDS (in combination with a macrolide plus ethambutol).
  • Treatment of TB in patients with AIDS who are taking PIs or NNRTIs.
  • Treatment of latent TB in patients intolerant to INH. Rifabutin x 4 months can be considered.

There's more to see -- the rest of this entry is available only to subscribers.

© 2000–2022 Unbound Medicine, Inc. All rights reserved